Clinical Trial Update: A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer [Phase 3]

View source ↗

Summary

This Phase 3 trial is evaluating pembrolizumab plus sacituzumab govitecan versus standard of care for locally advanced, unresectable, or metastatic urothelial c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Unresectable Urothelial Carcinoma
• Urothelial Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma | Phase 3 | Status: RECRUITING